Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: A population-based, prospective cohort study

The Lancet Respiratory Medicine

Volumn 1, Issue 10, 2013, Pages 779-785

  Guerra, Stefano ^a,c,d   Vasquez, Monica M ^a,b   Spangenberg, Amber ^a   Halonen, Marilyn ^a   Martinez, Fernando D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLARA CELL PROTEIN; SCGB1A1 PROTEIN, HUMAN; TUMOR MARKER; UTEROGLOBIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; EDUCATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENTIATION; SMOKING; YOUNG ADULT; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FORECASTING; HEALTH SURVEY; LUNG TUMOR; MORTALITY; SURVIVAL RATE; TRENDS; UNITED STATES;

ADULT; AGED; BIOMARKERS, TUMOR; CAUSE OF DEATH; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SURVIVAL RATE; TEXAS; UTEROGLOBIN; YOUNG ADULT;

EID: 84888877648     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70220-0     Document Type: Article

References (30)

1. Broeckaert F, Bernard A Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy 2000, 30:469-475.
2. Mukherjee AB, Zhang Z, Chilton BS Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. Endocr Rev 2007, 28:707-725.
3. Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers 2007, 12:445-467.
4. Shijubo N, Itoh Y, Yamaguchi T, et al. Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers. Eur Respir J 1997, 10:1108-1114.
5. Rava M, Tares L, Lavi I, et al. Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population. J Allergy Clin Immunol 2013, 132:230-232.
6. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008, 63:1058-1063.
7. Linnoila RI, Szabo E, DeMayo F, Witschi H, Sabourin C, Malkinson A The role of CC10 in pulmonary carcinogenesis: from a marker to tumor suppression. Ann NY Acad Sci 2000, 923:249-267.
8. Chen J, Lam S, Pilon A, McWilliams A, Macaulay C, Szabo E Higher levels of the anti-inflammatory protein CC10 are associated with improvement in bronchial dysplasia and sputum cytometric assessment in individuals at high risk for lung cancer. Clin Cancer Res 2008, 14:1590-1597.
9. Szabo E, Goheer A, Witschi H, Linnoila RI Overexpression of CC10 modifies neoplastic potential in lung cancer cells. Cell Growth Differ 1998, 9:475-485.
10. Yang Y, Zhang Z, Mukherjee AB, Linnoila RI Increased susceptibility of mice lacking Clara cell 10-kDa protein to lung tumorigenesis by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a potent carcinogen in cigarette smoke. J Biol Chem 2004, 279:29336-29340.
11. Hicks SM, Vassallo JD, Dieter MZ, et al. Immunohistochemical analysis of Clara cell secretory protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology 2003, 187:217-228.
12. Saha A, Lee YC, Zhang Z, Chandra G, Su SB, Mukherjee AB Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J Biol Chem 2010, 285:10822-10831.
13. Zhang Z, Kundu GC, Panda D, et al. Loss of transformed phenotype in cancer cells by overexpression of the uteroglobin gene. Proc Natl Acad Sci USA 1999, 96:3963-3968.
14. Lebowitz MD, Knudson RJ, Burrows B Tucson epidemiologic study of obstructive lung diseases. I: methodology and prevalence of disease. Am J Epidemiol 1975, 102:137-152.
15. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 1976, 113:587-600.
16. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
17. Davis KB, Fisher L, Gillespie MJ, Pettinger M A test of the National Death Index using the Coronary Artery Surgery Study (CASS). Control Clin Trials 1985, 6:179-191.
18. Secretan B, Straif K, Baan R, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009, 10:1033-1034. for the WHO International Agency for Research on Cancer Monograph Working Group.
19. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
20. Chen J, Lam S, Pilon A, McWilliams A, Melby J, Szabo E The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2007, 16:577-583.
21. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365:1184-1192.
22. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012, 176:573-585.
23. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
24. Yeager DS, Krosnick JA The validity of self-reported nicotine product use in the 2001-2008 National Health and Nutrition Examination Survey. Med Care 2010, 48:1128-1132.
25. West R, Zatonski W, Przewozniak K, Jarvis MJ Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and self-reported smoking rates in three countries. Cancer Epidemiol Biomarkers Prev 2007, 16:820-822.
26. Menvielle G, Boshuizen H, Kunst AE, et al. Occupational exposures contribute to educational inequalities in lung cancer incidence among men: Evidence from the EPIC prospective cohort study. Int J Cancer 2010, 126:1928-1935.
27. Doody MM, Hayes HM, Bilgrad R Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001, 11:46-50.
28. SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2012, National Cancer Institute, Bethesda, MD. N. Howlader, A. Noone, M. Krapcho (Eds.).
29. Hermans C, Bernard A Lung epithelium-specific proteins: characteristics and potential applications as markers. Am J Respir Crit Care Med 1999, 159:646-678.
30. Bernard AM, Roels HA, Buchet JP, Lauwerys RR Serum Clara cell protein: an indicator of bronchial cell dysfunction caused by tobacco smoking. Environ Res 1994, 66:96-104.